CURRICULUM VITAE
FOR
Ronald L. Baird, DO

3364 North 500 East

Provo, UT 84604
Phone: (801) 995-2634

dr.ronald.baird@gmail.com

EDUCATION AND CERTIFICATIONS

1998	Board Certification in Family Practice Medicine American Board of Family Medicine
1998	Family Practice Residency Utah Valley Family Practice Residency, IHC Hospital, Provo, Utah
1996	General Rotating Internship Park Lane Hospital, Kansas City, MO
1995	Doctor of Osteopathic Medicine University of Health Science College of Osteopathic Medicine Kansas city, MO
1990	Bachelors of Science, Biochemistry Brigham Young University, Provo, Utah

EMPLOYMENT HISTORY:

2020 – Present	**Olympus Healing Center - Medical Director** 2870 E 3300 S Salt Lake City, UT
2016 – Present	**Chateau Recovery - Medical Director** 375 Rainbow Ln Midway, UT
2017 – 2019	**Cirque Lodge Recovery - Medical Director** RR 3 Box A-10 Sundance, UT

EMPLOYMENT HISTORY (continued):

2017 – 2020	**Copper Sage Recovery - Medical Director** 14014 S 2200 W Bluffdale, UT
2016 – 2019	**Pinnacle Recovery - Medical Director** 6196 South Holladay Blvd Holladay, UT
2016 – 2018	**Daylight Recovery - Medical Director** 672 East Union Square Sandy, UT
2013 – 2017	**True North Treatment Center - Medical Director** 234 N Orem Blvd Orem, UT
2008 - 2010	**Clinical Investigator** Aspen Clinical Research, LLC Orem, UT
1998 – 2010	**President/Owner – Private Practice** Canyonview Family Practice Provo, UT
1997 – 2010	**Part-time Emergency Room Coverage** Orem Community Hospital Orem, UT
Jul ‘98 – Nov ‘98	**Full-time Faculty Member** Utah Valley Family Practice Residency
1997 - 1998	**Weekend Emergency Room Coverage** Sanpete Valley and Delta Hospitals
1992 – 1993	**Teaching Assistant** University of Health Sciences, Physiology Dept.
1992 – 1993	**Laboratory Teaching Assistant** University of Health Sciences, Osteopathic Manipulation Dept.
1992 (summer)	**Teaching Assistant** University of Health Sciences, Anatomy Dept.
1990 – 1991	**Laboratory Technician/Biochemist** Murdock Health Care, Quality Assurance Dept.

PROFESSIONAL LICENSE:

322409-1204	State of Utah Medical License Active License Expires 05/31/2022

PROFESSIONAL MEMBERSHIPS

- American Academy of Family Practice
- American College of Family Practitioners
- Utah Medical Association

PROFESSIONAL AFFILIATIONS:

- Utah Valley Regional Medical Center, Provo, UT
- Orem Community Hospital, Orem, UT
- Timpanogos Regional Hospital, Orem, UT

REFERENCES:

- References available upon request:

CLINICAL RESEARCH TRAINING:

THERAPEUTIC AREAS OF RESEARCH EXPERIENCE

ADME	Phase I, II clinical trials
Alzheimer's	Phase I, II clinical trials
Cardiology	Phase II, III clinical trials
Diabetes	Phase II, III clinical trials
Hypercholesterolemia	Phase III clinical trials
Hypertension	Phase III clinical trials
Acute / Chronic Pain	Phase I, II, III clinical trials

DETAILED CLINICAL TRIAL EXPERIENCE:

“A Phase 2a, Randomized, Blinded, Placebo and Active controlled, 2-Period Crossover Study to Assess the Analgesic Efficacy, Safety, and Tolerability of XXXXXXXXX in subjects with Post Herpetic Neuralgia (PHN)”

“A Multi-Center, Double Blind, Placebo-Controlled, Study to evaluate the Safety and Efficacy of Oral XXXXXXXX in Subjects with Euvolemic Hyponatremia”

“A Double Blind, Efficacy and Safety of Duloxetine versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder”

“A Phase I, Multi-Centered, Randomized, Placebo-Controlled, Double Blind Study to assess the Safety, Pharmcokinetics, Pharmcodynamics, and Immunogenicity of Intravenous XXXXXXXXX administered in a Single Dose, Dose Escalation stage followed by a Multi-Dose. Parrallel Treatment stage in patients with Mild to Moderate Alzheimers”

“A Phase IV, Double-Blind, Multi-Center, Placebo-Controlled, Randomized Withdrawal, Safety and Efficacy Study of XXXXXX in Adults age 18-55 with Attention Deficit Hyperactive Disorder (ADHD)”

“A Randomized, Double-Blind, Placebo Controlled, Dose ranging study of the Safety and Efficacy of XXXXXXXX in Subjects with Typee II Diabetes Mellitus on Stable Metformin Therapy”

“A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of XXXXXXXX vs. Standard Medical Care in Treating Iron Deficiency Anemia"

“A Multi-center, Randomized, Controlled Study to Investigate the Safety and Tolerability of A Single Dose of XXXXXXXX vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who are Not Dialysis Dependent"

“A Multi-center, Randomized, Active Controlled Study to Investigate the Efficacy and Safety of XXXXXXXX in Patients with Iron Deficiency Anemia (IDA)”

“A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of oral doses of XXXXXXXX 5, 10, and 30 mg and placebo on top of an established treatment regimen of either olanzapine, risperidone/paliperidone, quetiapine or aripirazole monotherapy in the treatment of Cognitive Impairment in Schizophrenia.”

“A Randomized, Double-Blind, Active-Controlled Crossover Study to Evaluate the Efficacy and Safety of XXXXXXXX Compared With Immediate-Release Oxycodone for the Management of Breakthrough Pain in Opioid Tolerant Patients With Chronic Pain, Followed by a 12-Week Open-Label Extension to Evaluate the Impact of XXXXXXXX on Patient Outcomes”

“A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Exploratory, 28-Day Study to Examine the Effects of XXXXXXXX on Blood Pressure and Glucose Tolerance in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance”

“The effect of insulin detemir in combination with XXXXXXXX and metformin compared to XXXXXXXX and metformin in subjects with type 2 diabetes. A 26-week, randomised, open-label, parallel-group, multicentre, multinational trial with a 26-week extension”

“A Randomized, Double-blind, Parallel-Group, Multicenter Study to Evaluate the Retention Rate, Efficacy, Safety, and Tolerability of XXXXXXXX, Topiramate and Levetiracetam as Adjunctive Therapy in Subjects with Partial Onset Seizures”

"Multicenter, Double-Blind, Randomized, Placebo-Controlled, Three-Arm, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXXXXX as Adjunctive Therapy in Subjects with Refractory Partial Seizures due to Epilepsy on up to Two Concomitant Antiepileptic Medications"

"Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of XXXXXXXX as Adjunctive Therapy in Subjects with Refractory Partial Epilepsy on up to Two Concomitant Antiepileptic Medications"

"A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of XXXXXXXX When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus"

"A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of XXXXXXXX Compared With Insulin in Subjects With Type 2 Diabetes Mellitus"